Vamorolone
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial.
Journal: Neurology
Published: July 30, 2026
Expanding Vamorolone Treatment Access for Canadians with Duchenne Muscular Dystrophy.
Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Published: July 13, 2026
Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial.
Journal: Neurology
Published: May 27, 2026
Vamorolone Safety, Pharmacokinetics, and Exploratory Efficacy in Duchenne Muscular Dystrophy: A Phase II, Nonrandomized, Multiple-Dose Study in 2-<4-Year-Old Boys.
Journal: Neurology
Published: May 15, 2026
Meta-analysis of clinical trials assessing the safety of pharmacological treatments for muscular degeneration in Duchenne muscular dystrophy.
Journal: BMC pharmacology & toxicology
Published: April 17, 2026
Treatment advances for Duchenne muscular dystrophy.
Journal: Current opinion in pediatrics
Published: April 01, 2026
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update.
Journal: Expert opinion on pharmacotherapy
Published: March 30, 2026
Post-marketing safety surveillance and signal characterization of the novel dissociative steroid Vamorolone in Duchenne muscular dystrophy: a comparative disproportionality analysis based on FAERS data.
Journal: Frontiers in pharmacology
Published: March 25, 2026
Regimen-dependent glucocorticoid effects improve muscle performance without altering CNS physiology in mdx mice.
Journal: The Journal of physiology
Published: March 15, 2026
From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians.
Journal: Neuromuscular disorders : NMD
Published: February 02, 2026
Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy.
Journal: Scientific reports
Published: December 22, 2025
Last Updated: 09/26/2026